Product Description
Terbutaline is a selective beta 2 agonist used predominantly in the treatment of asthma. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/7096576/)
Mechanisms of Action: ADR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous, Inhalant
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Saudi Arabia | Singapore | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Spain, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Asthma|Conjunctivitis, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2025-521230-29-00 | P3 |
Not yet recruiting |
Conjunctivitis, Allergic |
2029-09-01 |
|||
| TBS02 | P3 |
Suspended |
Asthma |
2026-12-01 |
14% |
2025-04-17 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/23/2022 |
News Article |
Geoffrey Fieger & Beam Legal Team, LLC Announces $97.4 Million Birth Trauma Verdict |
|
06/11/2021 |
News Article |
European Hematology Association - Restoration of T Helper Cell Imbalance in Immune Thrombocytopenia by β2-Adrenergic Receptor Agonists |
|
01/27/2021 |
News Article |
Symbicort Turbuhaler approved in China as an anti-inflammatory reliever in mild asthma |
|
09/30/2019 |
News Article |
Symbicort® Turbuhaler® now approved by Health Canada for use in mild persistent, moderate, or severe asthma |